Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 15: Perindopril - Endothliale Dysfunktion Abb. 16: Perindopril - Widerstandsarterien Abb. 17: Perindopril - Widerstandsarterien Aktuelles Bild - Abb. 18: Perindopril - Koronarreserve Abb. 19: Perindopril - Fibrinolyse Abb. 20: Perindopril - Antiatheriosklerotischer Effekt Abb. 21: Perindopril - Antiischämische Wirksamkeit Zum letzten Bild
Abbildung 18: Perindopril - Koronarreserve
As a result, the coronary reserve increased by 67 %. Also, the LV muscle mass index significantly decreased by 11 % after a 12-month perindopril treatment. Percent of increase in coronary reserve was more than expected by regression of LVH alone. Regression of fibrosis was demonstrated by perindopril in the non-pressure overloaded right ventricle and independently from local myocyte size. It seems to be due to direct/chronic effects of perindopril on collagen metabolism. Perindopril 4 to 8 mg, once daily, reverses both interstitial fibrosis and LV mass in patients with LVH and significantly restores coronary flow reserve in the long term treatment independently of its anti-hypertensive efficacy.
 
Perindopril - Koronarreserve
Vorheriges Bild Nächstes Bild   


Abbildung 18: Perindopril - Koronarreserve
As a result, the coronary reserve increased by 67 %. Also, the LV muscle mass index significantly decreased by 11 % after a 12-month perindopril treatment. Percent of increase in coronary reserve was more than expected by regression of LVH alone. Regression of fibrosis was demonstrated by perindopril in the non-pressure overloaded right ventricle and independently from local myocyte size. It seems to be due to direct/chronic effects of perindopril on collagen metabolism. Perindopril 4 to 8 mg, once daily, reverses both interstitial fibrosis and LV mass in patients with LVH and significantly restores coronary flow reserve in the long term treatment independently of its anti-hypertensive efficacy.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung